A rumor regarding Arcutis Biotherapeutics (ARQT) was highlighted in an alert sent to subscribers of Ben Harrington’s takeover-focused Betaville blog, contacts tell The Fly. Shares of the biotech company are up 54c, or 5%, to $11.95 in afternoon trading.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics price target raised to $20 from $18 at Needham
- Arcutis Biotherapeutics reports preliminary Q4 revenue $63M, consensus $54.95M
- Arcutis Biotherapeutics price target raised to $20 from $19 at Mizuho
- American Air upgraded, Nordstrom downgraded: Wall Street’s top analyst calls
- Arcutis Biotherapeutics initiated with a Buy at H.C. Wainwright